Irritable Bowel Syndrome with Constipation (IBS-C) Drug Market to Witness Growth Acceleration by 2029
The global irritable bowel syndrome with constipation (IBS-C) drug market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market include the rise in the geriatric population, increase in the prevalence of gastrointestinal diseases such as constipation, the surge in level of stress, and unhealthy diet. Moreover, some other factors that are expected to fuel the market growth include an increase in awareness programs regarding the treatment and management of IBS and a surge in inclination toward IBS products that enhance therapeutic outcomes. Furthermore, the untapped potential opportunity across developing economies presents lucrative opportunities for the growth of the market during the forecast period.
Irritable bowel syndrome (IBS) is
a common gastrointestinal disorder that affects the large intestine. Signs
& symptoms include abdominal pain, bloating, gas, cramping, and
constipation or diarrhea. There are three types of irritable bowel syndrome
such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed
IBS. Treatment of irritable bowel syndrome consists of stress relief, change in
diet, proper medicines, and counseling. Medications available for the treatment
of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone,
linaclotide, and others. Furthermore, antispasmodics are also used for the
treatment of irritable bowel syndrome, which includes dicyclomine, peppermint
oil, and hyoscyamine. In addition, an increase in the prevalence of gastrointestinal
diseases such as constipation and diarrhea due to changes in lifestyles, an
increase in the geriatric population, a surge in uptake of drugs such as
linaclotide and lubiprostone, and a rise in patient awareness toward the
treatment of irritable bowel syndrome are some other factors that will propel
the growth of the global IBS-C drug market during the forecast
period.
To Request a Sample of our Report on Irritable Bowel
Syndrome with Constipation (IBS-C) Drug Market: https://www.omrglobal.com/request-sample/ibs-c-drug-market
Market Coverage
•
The market number available for – 2021-2029
•
Base year- 2021
•
Forecast period- 2023-2029
Segment Covered-
·
By Drug Type
·
By Prescription Type
Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape: Catalent Pharma Solutions,
Inc., AstraZeneca plc, and Abbott Laboratories, among others.
IBS-C Drug Market Report by Segment
By Drug Type
• Lubiprostone
• Linaclotide
• Stimulant
Laxatives
• Osmotic
Laxatives
• Others
By Prescription Type
•
Prescription Drugs
•
Over-the-Counter Drugs
A
full Report of Irritable Bowel Syndrome with Constipation (IBS-C) Drug Market is
Available @ https://www.omrglobal.com/industry-reports/ibs-c-drug-market
IBS-C Drug Market
Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert research
analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an experienced
team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment